Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.